Fig. 3From: Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohortKaplan-Meier plot of retention times for patients with rheumatoid arthritis and concomitant Sjögren’s disease. A, Eligible abatacept, rituximab, and IL-6Ri treatment courses. B, Eligible etanercept and other tumour necrosis factor-inhibitor treatment courses. IL-6i, Interleukin-6 receptor-inhibitorBack to article page